Last update 21 Nov 2024

Rabies G protein vaccine (CPL Biologicals)

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Virus-like particle vaccine, Prophylactic vaccine

Synonyms

Rabies G protein nanoparticle vaccine - CPL Biologicals, Rabies G protein nanoparticle vaccine CPL Biologicals, Recombinant nanoparticle rabies vaccine - CPL Biologicals

+ [1]

Target

RABV-G

Mechanism

RABV-G inhibitors(RABV-G inhibitors), Immunostimulants

Therapeutic Areas

Infectious DiseasesOther Diseases

Active Indication-

Inactive Indication

Rabies

Originator Organization

Novavax, Inc.

Active Organization-

Inactive Organization

CPL Biologicals Pvt Ltd.

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

100 Clinical Results associated with Rabies G protein vaccine (CPL Biologicals)

100 Translational Medicine associated with Rabies G protein vaccine (CPL Biologicals)

100 Patents (Medical) associated with Rabies G protein vaccine (CPL Biologicals)

Literatures (Medical) associated with Rabies G protein vaccine (CPL Biologicals)

02 Nov 2021·Human Vaccines & ImmunotherapeuticsQ3 · MEDICINE

Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study

Q3 · MEDICINE

Article

Author: Desai, Maharshi ; Khobragade, Akash ; Kumar, Surendra ; V, Ramasubramanian ; Agrawal, Ashok Dilipkumar ; Gupta, Monica ; Satapathy, Durga ; Bhomia, Vinay ; H S, Ravish

BACKGROUNDRabies vaccines are lifesaving in human post animal exposure. However, the compliance to the complete course of vaccine is found to be only 60%. Hence, there is a need for safe and immunogenic, shorter course vaccine that can enhance the compliance and effectively prevent the disease.OBJECTIVESTo establish a noninferiority of a novel three-dose recombinant rabies G protein vaccine to be administered as simulated postexposure prophylaxis when compared to five-dose WHO prequalified vaccine for better safety and immunogenicity.METHODSA multi-centric, open label, assessor blind, center-specific block randomized, parallel design, phase III clinical study was conducted among 800 subjects. The eligible subjects were randomized in 2:1 ratio for recombinant rabies G protein vaccine and the reference vaccine. Subjects in recombinant rabies G protein vaccine arm received three doses of vaccine on days 0, 3, and 7, while subjects in reference vaccine arm received five doses of WHO prequalified vaccine on days 0, 3, 7, 14, and 28.RESULTSThe socio-demographic characteristics of the two arms were comparable. About 9.9% subjects in recombinant rabies G protein vaccine arm and 17.2% subjects in reference arm reported adverse events. The sero-protection on day 14 was found to be 99.24% and 97.72% in recombinant rabies G protein vaccine arm and reference vaccine arm respectively and the difference was statistically nonsignificant.CONCLUSIONThe novel three-dose recombinant rabies G protein vaccine administered as simulated postexposure prophylaxis was noninferior to five dose WHO prequalified vaccine in terms of safety and immunogenicity.

01 May 2000·VaccineQ3 · MEDICINE

Immune responses in mice, cattle and horses to a DNA vaccine for vesicular stomatitis

Q3 · MEDICINE

Article

Author: P.W Gordy ; J.D Cantlon ; R.A Bowen

Vesicular stomatitis (VS) virus causes an important clinical disease of cattle and horses in North America. In order for a vaccine to be useful in the control of VS, it must not only protect against disease, but allow ready differentiation of infected and vaccinated animals. In these studies, we evaluated neutralizing antibody responses in outbred mice, calves, and horses that received a DNA vaccine that expressed the glycoprotein (G) gene of VS New Jersey virus. The vaccine elicited antibody titers in individuals from each species, especially when two doses were administered, but the level of neutralizing antibody needed to confer protection is not known. In mice, co-administration of a plasmid that expressed interleukin-2 resulted in a significant, though modest, increase in antibody titers relative to use of the G gene vaccine alone. The effect of co-injecting putative immunostimulatory oligonucleotides was also evaluated. This treatment had no apparent effect in horses and was found to suppress immune responses to the G gene vaccine in mice. If the immune responses obtained in these studies prove to protect cattle and horses from infection with VS virus, DNA vaccination may become a useful tool for control of this disease.

01 Nov 1999·Gene TherapyQ3 · MEDICINE

Stable gene transfer to the nervous system using a non-primate lentiviral vector

Q3 · MEDICINE

Article

Author: S Yoon ; D Patil ; V N Kim ; K A Mitrophanous ; F J Wilkes ; A J Kingsman ; N D Mazarakis ; S M Kingsman ; J B Rohll

We have constructed a non-primate lentiviral vector system based on the equine infectious anaemia virus (EIAV). This system is able to transduce both dividing and non-dividing cells, including primary cultured hippocampal neurons and neurons and glia in the adult rat central nervous system (CNS), at efficiencies comparable with HIV-based vectors. We demonstrate that the only EIAV proteins required for this activity are gag/pol and that the only accessory protein required for vector production is rev. In addition, we show that the pol encoded dUTPase activity that is found in all non-primate lentiviruses is not required. The vectors can be pseudotyped with a range of envelopes including rabies G and MLV 4070A and can be concentrated to high titres. The ability of EIAV to infect mitotically inactive cells makes this vector an attractive alternative to the immunodeficiency viruses for gene therapy.

100 Deals associated with Rabies G protein vaccine (CPL Biologicals)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rabies	Phase 3	IN	CPL Biologicals Pvt Ltd.	14 Sep 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Rabies G protein vaccine (CPL Biologicals)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation